Metformin prevents experimental gentamicin-induced nephropathyby a mitochondria-dependent pathway

Kidney International

Volumn 77, Issue 10, 2010, Pages 861-869

  Morales, Ana I ^a   Detaille, Dominique ^a   Prieto, Marta ^a   Puente, Angel ^a   Briones, Elsa ^a   Arévalo, Miguel ^a   Leverve, Xavier ^b   López Novoa, José M ^a   El Mir, Mohamad Yehia ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSERM   (France)

Author keywords

Acute kidney injury; Gentamicin; Mitochondria; Oxidative stress; Renal protection

Indexed keywords

CYTOCHROME C; GENTAMICIN; METFORMIN; N ACETYL BETA GLUCOSAMINIDASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING; CONTROLLED STUDY; CREATININE CLEARANCE; ELECTRON TRANSPORT; ENZYME ACTIVITY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIPID PEROXIDATION; MALE; MITOCHONDRION; NONHUMAN; OXYGEN CONSUMPTION; PLEIOTROPY; PRIORITY JOURNAL; PROTEINURIA; RAT; URINE FLOW RATE;

EID: 77951879150     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.11     Document Type: Article

References (52)

1. Singenthaler W, Bonetti A, Luthy R. Aminoglycoside antibiotics in infectious diseases. Am J Med 1986; 80: 2-11.
2. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33: 900-911.
3. Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 2007; 223: 86-98.
4. Rodriguez-Barbero A, L'Azou B, Cambar J et al. Potential use of isolated glomeruli and cultured mesangial cells as in vitro models to assess nephrotoxicity. Cell Biol Toxicol 2000; 16: 143-153.
5. Martinez-Salgado C, Eleno N, Morales AI et al. Gentamicin treatment induces simultaneous mesangial proliferation and apoptosis in rats. Kidney Int 2004; 65: 2161-2171.
6. Hall AM, Unwin RJ. The not so 'Mighty Chondrion': emergence of renal diseases due to mitochondrial dysfunction. Nephron Physiol 2007; 105: 1-10.
7. Sanz AB, Santamaria B, Ruiz-Ortega R et al. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008; 19: 1634-1642.
8. Simmons CF, Bogusky RT, Humes HD. Inhibitory effects of gentamicin on renal mitochondrial oxidative phosphorylation. J Pharmacol Exp Ther 1980; 214: 709-715.
9. Kiritoshi S, Nishikawa T, Sonoda K et al. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 2003; 52: 2570-2577.
10. Plotnikov EY, Kazachenko AV, Vyssokikh MY et al. The role of mitochondria in oxidative and nitrosative stress during ischemia/reperfusion in the rat kidney. Kidney Int 2007; 72: 1493-1502.
11. Baliga R, Ueda N, Walker PD et al. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999; 31: 971-997.
12. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454.
13. Rodriguez-Barbero A, Lopez-Novoa JM, Arevalo M. Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats. Exp Nephrol 1997; 5: 47-54.
14. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med 2008; 36(Suppl 4): S216-S223.
15. Martinez-Salgado C, Eleno N, Tavares P et al. Involvement of oxygen reactive species on gentamicin-induced mesangial cell activation. Kidney Int 2002; 62: 1682-1692.
16. Servais H, Ortiz A, Devuyst O et al. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms, and potential approaches to modulation. Apoptosis 2008; 13: 11-32.
17. Walker PD, Shah SV. Gentamicin enhanced production of hydrogen peroxide by renal cortical mitochondria. Am J Physiol 1987; 253: C495-C499.
18. Morales AI, Buitrago JM, Santiago JM et al. Protective effect of trans-resveratrol on gentamicin-induced nephrotoxicity. Antioxid Redox Signal 2002; 4: 893-898.
19. Maldonado P, Barrera D, Rivero I et al. Antioxydant S-allylcysteine prevents gentamicin-induced oxidative stress and renal damage. Free Radic Biol Med 2003; 35: 317-324. (Pubitemid 37288932)
20. Bledsoe G, Crickman S, Mao J et al. Kallikrein/kinin protects against gentamicin-nephro-toxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 2006; 21: 624-633.
21. Priyamvada S, Priyadarshini M, Arivarasu NA et al. Studies of the protective effect of dietary fish oil on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney. Prostaglandin Leukot Essent Fatty Acids 2008; 78: 369-381.
22. Wiernsperger N. 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diabetes Vasc Dis 2007; 7: 204-210.
23. Guigas B, Detaille D, Chauvin C et al. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J 2004; 382: 877-884.
24. El-Mir MY, Detaille D, Villanueva GR et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 2008; 34: 77-87.
25. Detaille D, Guigas B, Chauvin C et al. Metformin prevents high glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54: 2179-2187.
26. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
27. Leverve X, Fontaine E. Role of substrates in the regulation of mitochondrial function in situ. IUBMB Life 2001; 52: 221-229.
28. El-Mir MY, Nogueira V, Fontaine E et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275: 223-228.
29. Batandier C, Leverve X, Fontaine E. Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I. J Biol Chem 2004; 279: 17197-17204.
30. Plotnikov EY, Kazachenko AV, Vyssokikh MY et al. The role of mitochondria in oxidative and nitrosative stress during ischemia/reperfusion in the rat kidney. Kidney Int 2007; 72: 1493-1502.
31. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 2003; 41: 1447-1452.
32. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24: 49-57.
33. Faure P, Rossini E, Wiernsperger N et al. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 1999; 48: 353-357.
34. Rösen P, Wiernsperger N. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab Res Rev 2006; 22: 323-330.
35. Gilbert DN, Wood C, Kohlhepp S et al. Polyaspartic acid prevents experimental amino-glycoside nephrotoxicity. J Infect Dis 1989; 159: 945-953.
36. Kimura N, Masuda S, Tanihara Y et al. Metformin is a superior substrate for renal organic cation transporter OCT-2 rather than hepatic OCT-1. Drug Metab Pharmacokinet 2005; 20: 379-386.
37. Schmitz C, Hilpert J, Jacobsen C et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002; 277: 618-622.
38. Bernardi P, Krauskopf A, Basso E et al. The mitochondrial permeability transition from in vitro artefact to disease target. FEBS J 2006; 273: 2077-2099.
39. Dumas JF, Argaud L, Cottet-Rousselle C et al. Effect of transient and permanent permeability transition pore opening on NAD(P)H localization in intact cells. J Biol Chem 2009; 284: 15117-15125.
40. Batandier C, Guigas B, Detaille D et al. The ROS production induced by a reverse-electron flux at respiratory chain complex I is hampered by metformin. J Biomembr Bioenerg 2006; 38: 33-42.
41. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase-development of the energy sensor concept. J Physiol 2006; 574: 7-15.
42. Lee MJ, Feliers D, Mariappan MM et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007; 292: P617-P627.
43. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346.
44. Koyner JL, Ali RS, Murray PT. Antioxidants. Do have a place in the prevention or therapy of acute kidney injury? Nephron Exp Nephrol 2008; 109: 109-117.
45. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
46. Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; 25: CD002967.
47. Barthelmebs M, Wiernsperger N, Krieger JP et al. Mild acute renal failure potentiates metformin accumulation in the diabetic rat kidney without further impairment of renal function. Diabetes Metab 2003; 29: 163-170.
48. Holstein A, Stumvoll M. Contraindications can damage your health. Is metformin a case in point? Diabetologia 2005; 48: 2454-2459.
49. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86: 271-278.
50. Santos B, Sayalero ML, Zarzuelo A et al. Determination of amikacin in biological tissues by HPLC. J Liq Chromatogh Rel Technol 2002; 25: 463-473. (Pubitemid 34225645)
51. Vincent AS, Lim BG, Tan J et al. Sulfite-mediated oxidative stress in kidney cells. Kidney Int 2004; 65: 393-402.
52. Wei Q, Dong G, Franklin J et al. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 2007; 72: 53-62.